Zealand Pharma A/S 2021 SR
The report highlights Zealand Pharma's commitment to corporate social responsibility during the 2021 fiscal year, focusing on peptide therapeutics for diabetes, rare diseases, obesity, and inflammatory diseases. Key achievements include the FDA approval and launch of Zegalogue and the introduction of environmental goals linked to management bonuses. The company emphasized diversity, reporting a 58% female workforce and 36% female representation on the Board of Directors. Additionally, Zealand Pharma focused on patient-centric development through collaborations with advocacy groups and maintained high employee engagement scores.
Company: Zealand Pharma A/S
Sector: Manufacturing
Country: Denmark
Year: 2021
Type: SR
Pages: 17
Back to company
Zealand Pharma A/S
Corporate Responsibility Report
The report highlights Zealand Pharma's commitment to corporate social responsibility during the 2021 fiscal year, focusing on peptide therapeutics for diabetes, rare diseases, obesity, and inflammatory diseases. Key achievements include the FDA approval and launch of Zegalogue and the introduction of environmental goals linked to management bonuses. The company emphasized diversity, reporting a 58% female workforce and 36% female representation on the Board of Directors. Additionally, Zealand Pharma focused on patient-centric development through collaborations with advocacy groups and maintained high employee engagement scores.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees